Drug Information Association (DIA) Annual Meeting

Jon Ernst (Vice President, In-Home Solutions, Decentralized Clinical Trials) discusses today's clinical trial landscape.

In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.

Carie Pierce, SVP, global head of growth & business development, DIA touches on the various themes of the sessions which were held at the 2024 Global Annual Meeting including regulatory, technology, and harmonization.

Pierce shares her greatest takeaways from this year's meeting in San Diego, CA.

Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.

In an interview with ACT editor Andy Studna at DIA 2024, Beakes-Read, head, global regulatory policy and intelligence, Johnson & Johnson Innovative Medicine highlights the integration of technological advancements into drug development and benefits patients are seeing from FDA's Accelerated Approval Program.

In an interview with ACT editor Andy Studna at DIA 2024, Cuff Shimooka, chief operating officer of TransCelerate Biopharma touches on how collaboration will be key to innovation in clinical research moving forward.

Breakout session discusses the impact of incorporating decentralized elements into oncology clinical trials on data integrity, patient safety, and regulatory approvals.

In an interview with ACT editor Andy Studna at DIA 2024, DiCicco, vice president, portfolio management, TransCelerate Biopharma highlights the use of artificial intelligence in clinical research from the perspectives of different stakeholders.

In an interview with ACT editor Andy Studna at DIA 2024, Hughes, co-founder and chief commercial officer of CluePoints touches on collaboration with FDA and using artificial intelligence in clinical research.

Session highlights the value of simulations such as data analysis and endpoint selection in clinical development.

In an interview with ACT editor Andy Studna at DIA 2024, Dabbs, vice president, global product strategy, IQVIA highlights challenges with tech overload and how stakeholders can choose which solution(s) are best for their studies.

Fathallah shares his thoughts on the recent DIA 2023 Annual Meeting in Boston, MA.

Perceived barriers of DCTs can be quickly overcome to ensure their viability in clinical research.

How will AI best be positioned to help safety professionals best utilize their time and resources?

"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals at DIA 2023.

DIA 2023 panel discussed personal experiences in clinical trials and offer suggestions for improvements to focus on the participants.

Jaydev Thakkar, chief operating officer, Biofourmis discusses how Biofourmis got involved with the CancerX Initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis discusses the work his organization is doing within the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis gives an overview of the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of the EFGCP eConsent Initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of eConsent at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders discusses takeaways from a 2023 DIA session she spoke at on eConsent.

Session at DIA discusses the International Medical Device Regulators Forum (IMDRF), its importance and how harmonization could be improved.

CDER and CBER leaders update initiatives in the rare disease space within the past year.

Emily Botto, research analyst, Tufts CSDD speaks about a recent study on the impact of exclusionary behaviors on team dynamics conducted by Tufts at the 2023 DIA annual meeting in Boston, MA.

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about returning patient data at the 2023 DIA annual meeting in Boston, MA.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Venkatraman Balasubramanian, SVP and global head, industry solutions, healthcare and life sciences, Orion Innovation, discusses feedback from the audience during his session, “The Case for Generating Synthetic Data as Real-World Data: Regulatory and Planning Perspectives.”